67. 多発性嚢胞腎 Disease details / Clinical trials / Drug dev / DR info

15 or 45 MG
   Nordsjællands Hospital, Department of Cardiology, Nephrology and Endocrinology
      2018   Phase 4   EUCTR2017-004115-39-DK   Denmark
30 or 60 MG
   Nordsjællands Hospital, Department of Cardiology, Nephrology and Endocrinology
      2018   Phase 4   EUCTR2017-004115-39-DK   Denmark
30 or 90 MG
   Nordsjællands Hospital, Department of Cardiology, Nephrology and Endocrinology
      2018   Phase 4   EUCTR2017-004115-39-DK   Denmark
ABBV-CLS-628
   AbbVie
      2025   Phase 2   NCT06902558   -
AD libitum water intake
   Cambridge University Hospitals NHS Foundation Trust
      2016   -   NCT02933268   United Kingdom
AL01211
   AceLink Therapeutics, Inc.
      2021   Phase 1   NCT04908462   Australia
Amias
   Addenbrooke's Hospital Trust
      2005   Phase 4   EUCTR2005-003182-16-GB   United Kingdom
Amiloride
   Erasmus University Medical Centre Rotterdam
      2021   Phase 4   EUCTR2020-000433-40-NL   Netherlands
Amiloride HCL 5MG TAB
   Erasmus Medical Center
      2022   Phase 4   NCT05228574   Netherlands
Aminohippurate
   University of Colorado, Denver
      2020   -   NCT04407481   United States
Amlodipine
   Addenbrooke's Hospital Trust
      2005   Phase 4   EUCTR2005-003182-16-GB   United Kingdom
ANTI-hypertensive medications
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      2003   -   NCT00067977   United States
Antihypertensive drugs
   Mei changlin
      2013   Phase 2   NCT01932450   China
Aprinox
   Addenbrooke's Hospital Trust
      2005   Phase 4   EUCTR2005-003182-16-GB   United Kingdom
Atorvastatin 20 MG oral tablet
   Taipei Medical University Shuang Ho Hospital
      2023   Phase 2   NCT05870007   Taiwan
Bardoxolone methyl
   Reata Pharmaceuticals, Inc.
      2019   Phase 3   JPRN-UMIN000039943   Japan,North America,Australia,Europe
   Reata, a wholly owned subsidiary of Biogen
      2019   Phase 3   NCT03749447   Australia;France;Japan;Puerto Rico;Spain;United States
Bardoxolone methyl 10 MG
   REATA PHARMACEUTICALS, INC.
      2019   Phase 3   EUCTR2018-004651-20-IT   Australia;Belgium;Czech Republic;Czechia;France;Germany;Italy;Spain;United Kingdom;United States
   Reata Pharmaceuticals, Inc.
      2023   Phase 3   EUCTR2018-004651-20-PL   Australia;Belgium;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Italy;Japan;Poland;Spain;United Kingdom;United States
      2023   Phase 3   EUCTR2018-004651-20-HU   Australia;Belgium;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Italy;Japan;Poland;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2018-004651-20-GB   Australia;Belgium;Czech Republic;France;Germany;Italy;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2018-004651-20-DE   Australia;Belgium;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Italy;Japan;Poland;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-004651-20-FR   Australia;Belgium;Czech Republic;Denmark;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-004651-20-ES   Australia;Belgium;Czech Republic;France;Germany;Italy;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-004651-20-CZ   Australia;Belgium;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Italy;Japan;Poland;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-004651-20-BE   Australia;Belgium;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Italy;Japan;Poland;Spain;United Kingdom;United States
Bardoxolone methyl 15 MG
   Reata Pharmaceuticals, Inc.
      2023   Phase 3   EUCTR2018-004651-20-PL   Australia;Belgium;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Italy;Japan;Poland;Spain;United Kingdom;United States
      2023   Phase 3   EUCTR2018-004651-20-HU   Australia;Belgium;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Italy;Japan;Poland;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2018-004651-20-GB   Australia;Belgium;Czech Republic;France;Germany;Italy;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2018-004651-20-DE   Australia;Belgium;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Italy;Japan;Poland;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-004651-20-FR   Australia;Belgium;Czech Republic;Denmark;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-004651-20-ES   Australia;Belgium;Czech Republic;France;Germany;Italy;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-004651-20-CZ   Australia;Belgium;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Italy;Japan;Poland;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-004651-20-BE   Australia;Belgium;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Italy;Japan;Poland;Spain;United Kingdom;United States
Bardoxolone methyl 20 MG
   REATA PHARMACEUTICALS, INC.
      2019   Phase 3   EUCTR2018-004651-20-IT   Australia;Belgium;Czech Republic;Czechia;France;Germany;Italy;Spain;United Kingdom;United States
   Reata Pharmaceuticals, Inc.
      2023   Phase 3   EUCTR2018-004651-20-PL   Australia;Belgium;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Italy;Japan;Poland;Spain;United Kingdom;United States
      2023   Phase 3   EUCTR2018-004651-20-HU   Australia;Belgium;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Italy;Japan;Poland;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2018-004651-20-GB   Australia;Belgium;Czech Republic;France;Germany;Italy;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2018-004651-20-DE   Australia;Belgium;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Italy;Japan;Poland;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-004651-20-FR   Australia;Belgium;Czech Republic;Denmark;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-004651-20-ES   Australia;Belgium;Czech Republic;France;Germany;Italy;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-004651-20-CZ   Australia;Belgium;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Italy;Japan;Poland;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-004651-20-BE   Australia;Belgium;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Italy;Japan;Poland;Spain;United Kingdom;United States
Bardoxolone methyl 5 MG
   REATA PHARMACEUTICALS, INC.
      2019   Phase 3   EUCTR2018-004651-20-IT   Australia;Belgium;Czech Republic;Czechia;France;Germany;Italy;Spain;United Kingdom;United States
   Reata Pharmaceuticals, Inc.
      2023   Phase 3   EUCTR2018-004651-20-PL   Australia;Belgium;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Italy;Japan;Poland;Spain;United Kingdom;United States
      2023   Phase 3   EUCTR2018-004651-20-HU   Australia;Belgium;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Italy;Japan;Poland;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2018-004651-20-GB   Australia;Belgium;Czech Republic;France;Germany;Italy;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2018-004651-20-DE   Australia;Belgium;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Italy;Japan;Poland;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-004651-20-FR   Australia;Belgium;Czech Republic;Denmark;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-004651-20-ES   Australia;Belgium;Czech Republic;France;Germany;Italy;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-004651-20-CZ   Australia;Belgium;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Italy;Japan;Poland;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-004651-20-BE   Australia;Belgium;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Italy;Japan;Poland;Spain;United Kingdom;United States
Bardoxolone methyl capsules
   Reata, a wholly owned subsidiary of Biogen
      2017   Phase 2   NCT03366337   United States
Bardoxolone methyl oral capsule
   Reata, a wholly owned subsidiary of Biogen
      2019   Phase 3   NCT03918447   Australia;Belgium;Czechia;France;Germany;Italy;Japan;Spain;United Kingdom;United States
Bardoxolone metile
   REATA PHARMACEUTICALS, INC.
      2019   Phase 3   EUCTR2018-004651-20-IT   Australia;Belgium;Czech Republic;Czechia;France;Germany;Italy;Spain;United Kingdom;United States
Bendroflumethiazide
   Addenbrooke's Hospital Trust
      2005   Phase 4   EUCTR2005-003182-16-GB   United Kingdom
Bifidobacterium
   Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
      2024   Phase 1-2   ChiCTR2400092731   China
BIM 23014
   DIPAK Consortium
      2012   Phase 3   EUCTR2011-005017-37-NL   Netherlands
Bisoprolol
   Addenbrooke's Hospital Trust
      2005   Phase 4   EUCTR2005-003182-16-GB   United Kingdom
Blood draw
   Ohio State University
      2024   -   NCT06325644   United States
Blood sample
   Assistance Publique - Hôpitaux de Paris
      2024   -   NCT06147414   France
Body composition
   Ohio State University
      2024   -   NCT06325644   United States
Bosutinib
   PFIZER INC.
      2011   -   EUCTR2010-023017-65-IT   Australia;Canada;Czech Republic;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Lithuania;Poland;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
   PFIZER, S.L.U.
      2011   -   EUCTR2010-023017-65-ES   Czech Republic;Hungary;Italy;Lithuania;Poland;Slovakia;Spain;Sweden;United Kingdom
   Pfizer
      2010   Phase 2   NCT01233869   Australia;Canada;Czech Republic;Hungary;Italy;Korea, Republic of;Lithuania;Moldova, Republic of;Poland;Romania;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
   Pfizer Inc.
      2011   -   EUCTR2010-023017-65-CZ   Australia;Bulgaria;Canada;Czech Republic;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Lithuania;Moldova, Republic of;Poland;Romania;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
   Pfizer Inc., 235 East 42nd Street, New York, NY 10017
      2012   Phase 2   EUCTR2010-023017-65-BG   Australia;Bulgaria;Canada;Czech Republic;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Lithuania;Moldova, Republic of;Poland;Romania;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2011   Phase 2   EUCTR2010-023017-65-SK   Australia;Bulgaria;Canada;Czech Republic;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Lithuania;Moldova, Republic of;Poland;Romania;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2011   -   EUCTR2010-023017-65-SE   Australia;Bulgaria;Canada;Czech Republic;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Lithuania;Moldova, Republic of;Poland;Romania;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2011   -   EUCTR2010-023017-65-PL   Czech Republic;Hungary;Italy;Lithuania;Poland;Slovakia;Spain;Sweden;United Kingdom
      2011   -   EUCTR2010-023017-65-LT   Czech Republic;Hungary;Italy;Lithuania;Poland;Slovakia;Spain;Sweden;United Kingdom
      2011   -   EUCTR2010-023017-65-HU   Australia;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Lithuania;Moldova, Republic of;Poland;Romania;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2011   Phase 2   EUCTR2010-023017-65-GB   Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Lithuania;Poland;Romania;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
C03xa01
   University Clinic in Nephrology and Hypertension, Department of Medical Research
      2014   -   EUCTR2014-001973-15-DK   Denmark
Calcineurin inhibitors maintenance
   Assistance Publique - Hôpitaux de Paris
      2014   Phase 3   NCT02134899   France
Candesartan
   Addenbrooke's Hospital Trust
      2005   Phase 4   EUCTR2005-003182-16-GB   United Kingdom
Candesartan and cilnidipine
   Kyorin University
      2007   Phase 4   NCT00541853   Japan
Candesartan plus NON-CCB agents
   Kyorin University
      2007   Phase 4   NCT00541853   Japan
Cardura
   Addenbrooke's Hospital Trust
      2005   Phase 4   EUCTR2005-003182-16-GB   United Kingdom
Certican
   Novartis Pharma GmbH
      2007   -   EUCTR2006-001485-16-FR   Austria;France;Germany
Certican tabletten
   Novartis Pharma GmbH
      2006   -   EUCTR2006-001485-16-DE   Austria;France;Germany
      2006   -   EUCTR2006-001485-16-AT   Austria;France;Germany
CGM/CKM
   Ohio State University
      2024   -   NCT06325644   United States
Cilnidipine
   Ministry of Health, Labour and Welfare, Japan
      2009   Phase 2   NCT00890279   Japan
Cohort 1: JMKX003142 and itraconazole
   Jemincare
      2024   Phase 1   NCT06658964   -
Cohort 2: JMKX003142 and rifampicin
   Jemincare
      2024   Phase 1   NCT06658964   -
Conventional therapy
   Mario Negri Institute for Pharmacological Research
      2010   Phase 2/Phase 3   NCT01223755   Italy
      2007   Phase 2   NCT00491517   Italy
Curcumin
   University of Colorado, Denver
      2015   Phase 4   NCT02494141   United States
Dapagliflozin
   Department of Endocrinology, Metabolism and Nephrology, Keio University School of Medicine
      2021   -   JPRN-UMIN000046275   Japan
Diet and water adjustment
   Tufts Medical Center
      2014   Phase 2/Phase 3   NCT02225860   United States
Doxazosin
   Addenbrooke's Hospital Trust
      2005   Phase 4   EUCTR2005-003182-16-GB   United Kingdom
Emodin
   Zhi-Hong Liu, M.D.
      2008   -   NCT00801268   China
Empagliflozin
   Cantonal Hospital Graubuenden
      2024   Phase 4   NCT06435858   Switzerland
   University of Colorado, Denver
      2022   Phase 2   NCT05510115   United States
Empagliflozin 10 MG
   Hannover Medical School
      2024   Phase 4   NCT06391450   Germany
Everolimus
   A. Manzoni Hospital
      2008   Phase 2/Phase 3   NCT01009957   Italy
   Assistance Publique - Hôpitaux de Paris
      2014   Phase 3   NCT02134899   France
   Novartis Pharma GmbH
      2007   -   EUCTR2006-001485-16-FR   Austria;France;Germany
      2006   -   EUCTR2006-001485-16-DE   Austria;France;Germany
      2006   -   EUCTR2006-001485-16-AT   Austria;France;Germany
   Novartis Pharmaceuticals
      2006   Phase 4   NCT00414440   Austria;France;Germany
G1117337
   GALAPAGOS NV
      2020   Phase 2   EUCTR2019-003521-21-IT   Belgium;Bulgaria;Czech Republic;Germany;Greece;Ireland;Italy;Netherlands;United Kingdom
   Galapagos NV
      2020   Phase 2   EUCTR2019-003521-21-NL   Belgium;Czech Republic;Germany;Italy;Netherlands;Spain
      2020   Phase 2   EUCTR2019-003521-21-DE   Belgium;Czech Republic;Germany;Italy;Netherlands;Spain
      2020   Phase 2   EUCTR2019-003521-21-CZ   Belgium;Czech Republic;Germany;Italy;Netherlands;Spain
      2020   Phase 2   EUCTR2019-003521-21-BE   Belgium;Czech Republic;Germany;Italy;Netherlands;Spain
      -   Phase 2   EUCTR2019-003521-21-ES   Belgium;Czech Republic;Germany;Italy;Netherlands;Spain
Genetic polymorphisms
   Ospedale San Raffaele
      2006   -   NCT06416761   Italy
GENZ-682452-AU
   GENZYME CORPORATION
      2018   Phase 2   EUCTR2017-004084-12-IT   Australia;Austria;Belgium;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Spain;Taiwan;United Kingdom;United States
   Genzyme Corporation
      2019   Phase 2   EUCTR2017-004084-12-RO   Australia;Austria;Belgium;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Spain;Switzerland;Taiwan;United Kingdom;United States
      2019   Phase 2   EUCTR2017-004084-12-NL   Argentina;Australia;Austria;Belgium;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Spain;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 2   EUCTR2017-004084-12-GB   Australia;Austria;Belgium;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Spain;Switzerland;Taiwan;United Kingdom;United States
      2019   Phase 2   EUCTR2017-004084-12-AT   Australia;Austria;Belgium;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Spain;Switzerland;Taiwan;United Kingdom;United States
      2018   Phase 2   EUCTR2017-004084-12-PT   Australia;Austria;Belgium;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Spain;Switzerland;Taiwan;United Kingdom;United States
      2018   Phase 2   EUCTR2017-004084-12-ES   Australia;Austria;Belgium;Canada;China;Czech Republic;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Spain;Switzerland;Taiwan;United Kingdom;United States
      2018   Phase 2   EUCTR2017-004084-12-DK   Australia;Austria;Belgium;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Spain;Switzerland;Taiwan;United Kingdom;United States
      2018   Phase 2   EUCTR2017-004084-12-DE   Australia;Austria;Belgium;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Spain;Switzerland;Taiwan;United Kingdom;United States
      2018   Phase 2   EUCTR2017-004084-12-CZ   Australia;Austria;Belgium;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Spain;Taiwan;United Kingdom;United States
      2018   Phase 2   EUCTR2017-004084-12-BE   Australia;Austria;Belgium;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Spain;Taiwan;United Kingdom;United States
GLPG2737
   GALAPAGOS NV
      2020   Phase 2   EUCTR2019-003521-21-IT   Belgium;Bulgaria;Czech Republic;Germany;Greece;Ireland;Italy;Netherlands;United Kingdom
   Galapagos NV
      2020   Phase 2   NCT04578548   Belgium;Czechia;Germany;Italy;Netherlands;Poland;Spain
      2020   Phase 2   EUCTR2019-003521-21-NL   Belgium;Czech Republic;Germany;Italy;Netherlands;Spain
      2020   Phase 2   EUCTR2019-003521-21-DE   Belgium;Czech Republic;Germany;Italy;Netherlands;Spain
      2020   Phase 2   EUCTR2019-003521-21-CZ   Belgium;Czech Republic;Germany;Italy;Netherlands;Spain
      2020   Phase 2   EUCTR2019-003521-21-BE   Belgium;Czech Republic;Germany;Italy;Netherlands;Spain
      -   Phase 2   EUCTR2019-003521-21-ES   Belgium;Czech Republic;Germany;Italy;Netherlands;Spain
GSK4771261
   GlaxoSmithKline
      2024   Phase 1   NCT06734234   Belgium;France;Germany;Netherlands;Spain;United Kingdom
GZ/SAR402671
   GENZYME CORPORATION
      2018   Phase 2   EUCTR2017-004084-12-IT   Australia;Austria;Belgium;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Spain;Taiwan;United Kingdom;United States
   SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
      2021   Phase 3   EUCTR2020-004400-34-IT   Argentina;Australia;Belgium;Canada;China;Czechia;Denmark;France;Germany;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Romania;Spain;Taiwan;Turkey;United Kingdom
HCT
   University Medical Center Groningen
      2018   Phase 2   EUCTR2017-003864-10-NL   Netherlands
High water intake
   Cambridge University Hospitals NHS Foundation Trust
      2016   -   NCT02933268   United Kingdom
   The Rogosin Institute
      2017   -   NCT03102632   United States
Hydralazine
   University of Kansas Medical Center
      2018   Early Phase 1   NCT03423810   United States
Hydrochlorothiazide
   University Medical Center Groningen
      2018   Phase 2   EUCTR2017-003864-10-NL   Netherlands
Hydrochlorothiazide 25 MG
   University Medical Center Groningen
      2024   Phase 3   NCT05373264   Belgium;France;Germany;Netherlands;Spain;United Kingdom;United States
Hyperpolarized [1-13C]pyruvate
   Aarhus University
      2022   Phase 2   EUCTR2021-002551-11-DK   Denmark
Imidapril
   Ministry of Health, Labour and Welfare, Japan
      2009   Phase 2   NCT00890279   Japan
Intravenous injection autologous mesenchymal stem cells
   Royan Institute
      2014   Phase 1   NCT02166489   Iran, Islamic Republic of
Iohexol
   University of Colorado, Denver
      2020   -   NCT04407481   United States
Istin
   Addenbrooke's Hospital Trust
      2005   Phase 4   EUCTR2005-003182-16-GB   United Kingdom
Jinarc
   IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
      2018   Phase 2   EUCTR2017-004701-40-IT   Italy
   Otsuka Pharmaceutical Development & Commercialization, Inc.
      2016   Phase 3   EUCTR2014-001501-41-BE   Argentina;Belgium;France;Germany;Japan;United States
      2015   Phase 3   EUCTR2014-001501-41-FR   Argentina;Belgium;France;Germany;Japan;United States
Jinarc - 15 MG - compressa - USO orale - blister (ALU/PVC) - 28 compresse
   U.O. NEFROLOGIA, DIALISI E TRAPIANTO AZIENDA OSPEDALIERO UNIVERSITARIA POLICLINICO DI BARI
      2018   Phase 3   EUCTR2018-000477-77-IT   Italy
Jinarc - 30 MG - compressa - USO orale - blister (ALU/PVC) - 28 compresse
   U.O. NEFROLOGIA, DIALISI E TRAPIANTO AZIENDA OSPEDALIERO UNIVERSITARIA POLICLINICO DI BARI
      2018   Phase 3   EUCTR2018-000477-77-IT   Italy
Jinarc - tolvaptan tablets
   Nordsjællands Hospital, Department of Cardiology, Nephrology and Endocrinology
      2018   Phase 4   EUCTR2017-004115-39-DK   Denmark
Jinarc 15 MG tablets, jinarc 45 MG tablets
   Nordsjællands Hospital, Department of Cardiology, Nephrology and Endocrinology
      2018   Phase 4   EUCTR2017-004115-39-DK   Denmark
Jinarc 30 MG tablet
   Otsuka Pharmaceutical Development & Commercialization, Inc.
      2023   Phase 3   EUCTR2020-005992-10-PL   Belgium;Canada;Czechia;France;Germany;Italy;Poland;Spain;United Kingdom;United States
      2023   Phase 3   EUCTR2020-005992-10-BE   Belgium;Canada;Czechia;France;Germany;Italy;Poland;Spain;United Kingdom;United States
      -   Phase 3   EUCTR2020-005992-10-DE   Belgium;Canada;Czechia;France;Germany;Italy;Poland;Spain;United Kingdom;United States
Jinarc 30 MG tablets, 90 MG tablets
   Nordsjællands Hospital, Department of Cardiology, Nephrology and Endocrinology
      2018   Phase 4   EUCTR2017-004115-39-DK   Denmark
Jinarc 30 MG tablets, jinarc 60 MG tablets
   Nordsjællands Hospital, Department of Cardiology, Nephrology and Endocrinology
      2018   Phase 4   EUCTR2017-004115-39-DK   Denmark
Jinarc® 15MG tablet
   Otsuka Pharmaceutical Development & Commercialization, Inc.
      2023   Phase 3   EUCTR2020-005992-10-PL   Belgium;Canada;Czechia;France;Germany;Italy;Poland;Spain;United Kingdom;United States
      2023   Phase 3   EUCTR2020-005992-10-BE   Belgium;Canada;Czechia;France;Germany;Italy;Poland;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2016-000187-42-IT   Belgium;Germany;Hungary;Italy;Poland;Spain;United Kingdom
      2016   Phase 3   EUCTR2016-000187-42-GB   Belgium;Germany;Italy;United Kingdom
      2016   Phase 3   EUCTR2016-000187-42-DE   Belgium;Germany;Italy;United Kingdom
      2016   Phase 3   EUCTR2016-000187-42-BE   Belgium;Germany;Italy;United Kingdom
      -   Phase 3   EUCTR2020-005992-10-DE   Belgium;Canada;Czechia;France;Germany;Italy;Poland;Spain;United Kingdom;United States
Jinarc® 30 tablet
   Otsuka Pharmaceutical Development & Commercialization, Inc.
      2016   Phase 3   EUCTR2016-000187-42-IT   Belgium;Germany;Hungary;Italy;Poland;Spain;United Kingdom
      2016   Phase 3   EUCTR2016-000187-42-GB   Belgium;Germany;Italy;United Kingdom
      2016   Phase 3   EUCTR2016-000187-42-DE   Belgium;Germany;Italy;United Kingdom
      2016   Phase 3   EUCTR2016-000187-42-BE   Belgium;Germany;Italy;United Kingdom
JMKX003142 will BE administered orally
   Jemincare
      2025   Phase 2   NCT06800651   -
Ketogenic diet
   Ohio State University
      2024   -   NCT06325644   United States
Ketone ester
   Universitair Ziekenhuis Brussel
      2023   Phase 2   NCT06100133   -
Ketone/glucose monitoring
   Ohio State University
      2024   -   NCT06325644   United States
Lanreotide
   Assistance Publique - Hôpitaux de Paris
      2014   Phase 3   NCT02127437   France
   Radboud University
      2011   -   NCT01354405   Netherlands
      2008   Phase 2/Phase 3   NCT00771888   Belgium;Netherlands
      2007   Phase 2/Phase 3   NCT00565097   Belgium;Netherlands
   University Medical Center Groningen
      2012   Phase 3   NCT01616927   Netherlands
Lanreotide acetate
   DIPAK Consortium
      2012   Phase 3   EUCTR2011-005017-37-NL   Netherlands
Leuprorelin
   University Medical Center Groningen
      2022   Phase 2   NCT05478083   Netherlands
Lisinopril
   Addenbrooke's Hospital Trust
      2005   Phase 4   EUCTR2005-003182-16-GB   United Kingdom
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      2006   Phase 3   NCT01885559   United States
      2006   Phase 3   NCT00283686   United States
Lixivaptan
   Palladio Biosciences
      2022   Phase 3   NCT05208866   United States
      2021   Phase 3   NCT04064346   Argentina;Australia;Bulgaria;Canada;Chile;Hungary;Israel;Italy;Mexico;Poland;Romania;Slovakia;Spain;Turkey;United Kingdom;United States
      2020   Phase 3   NCT04152837   United States
      2019   -   NCT03717181   United States
      2018   Phase 2   NCT03487913   United States
   Palladio Biosciences, Inc.
      2022   Phase 3   EUCTR2021-003062-12-IT   Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;France;Georgia;Hungary;Israel;Italy;Mexico;Peru;Poland;Romania;Serbia;Slovakia;Spain;Turkey;Ukraine;United Kingdom;United States
LONG-acting somatostatin
   Mario Negri Institute for Pharmacological Research
      2006   Phase 3   NCT00309283   Italy
Losartan
   Shanghai Changzheng Hospital
      2011   -   ChiCTR-TRC-11001282   China
LOW blood pressure control
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      2006   Phase 3   NCT00283686   United States
Lucrin
   University Medical Center Groningen
      2021   Phase 2   EUCTR2020-005949-16-NL   Germany;Netherlands
Metformin
   Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari
      2019   Phase 3   NCT03764605   Italy
   U.O. NEFROLOGIA, DIALISI E TRAPIANTO AZIENDA OSPEDALIERO UNIVERSITARIA POLICLINICO DI BARI
      2018   Phase 3   EUCTR2018-000477-77-IT   Italy
   University Medical Center Groningen
      2018   Phase 2   EUCTR2017-003864-10-NL   Netherlands
   University of Colorado, Denver
      2016   Phase 2   NCT02903511   United States
Metformin XR
   The University of Queensland
      2022   Phase 3   NCT04939935   Australia;New Zealand;United Kingdom
Metformina
   U.O. NEFROLOGIA, DIALISI E TRAPIANTO AZIENDA OSPEDALIERO UNIVERSITARIA POLICLINICO DI BARI
      2018   Phase 3   EUCTR2018-000477-77-IT   Italy
Midazolam
   Vertex Pharmaceuticals Incorporated
      2024   Phase 1   NCT06345755   Canada;United States
Monocor
   Addenbrooke's Hospital Trust
      2005   Phase 4   EUCTR2005-003182-16-GB   United Kingdom
NG-monomethyl-L-arginine
   Regional Hospital Holstebro
      2006   Phase 1   NCT00345137   -
Niacinamide
   Alan Yu, MB, BChir
      2014   Phase 2   NCT02140814   United States
   University of Kansas Medical Center
      2015   Phase 2   NCT02558595   United States
Nitrate-depleted beetroot juice
   Western Sydney Local Health District
      2022   -   NCT05401409   Australia
Octeotride
   Federico II University
      2009   Phase 2/Phase 3   NCT02119052   -
      2009   Phase 2/Phase 3   NCT02119013   -
Octreotide
   IST. DI RICERCHE FARMACOLOG. M. NEGRI
      2011   Phase 3   EUCTR2011-000138-12-IT   Italy
      2009   Phase 3   EUCTR2009-012376-27-IT   Italy
      2006   Phase 3   EUCTR2005-005552-41-IT   Italy
   Mario Negri Institute for Pharmacological Research
      2024   -   NCT06193616   Italy
   Mayo Clinic
      2007   Phase 2/Phase 3   NCT00426153   United States
Octreotide LAR
   Mario Negri Institute for Pharmacological Research
      2018   Phase 2   NCT03541447   Italy
Octreotide-LAR
   Mario Negri Institute for Pharmacological Research
      2011   Phase 3   NCT01377246   Italy
OPC-41061
   Otsuka Maryland Research Institute, Inc.
      2007   Phase 3   EUCTR2006-002768-24-FR   Belgium;Denmark;France;Germany;Italy;United Kingdom
   Otsuka Pharmaceutical Co., Ltd.
      2009   Phase 3   NCT01022424   Japan
      2006   Phase 2   NCT00841568   Japan
   Otsuka Pharmaceutical Development & Commercialization, Inc
      2011   -   EUCTR2010-018401-10-NL   Afghanistan;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Romania;Russian Federation;United Kingdom;United States
      2010   Phase 3   EUCTR2010-018401-10-GB   Argentina;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Romania;Russian Federation;United Kingdom;United States
      2010   Phase 3   EUCTR2010-018401-10-FR   Belgium;France;Germany;Italy;Netherlands;United Kingdom
      2010   -   EUCTR2010-018401-10-DE   Argentina;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Romania;Russian Federation;United Kingdom;United States
      2010   Phase 3   EUCTR2010-018401-10-BE   Argentina;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Romania;Russian Federation;United Kingdom;United States
   Otsuka Pharmaceutical Development & Commercialization, Inc.
      2023   Phase 3   EUCTR2020-005992-10-PL   Belgium;Canada;Czechia;France;Germany;Italy;Poland;Spain;United Kingdom;United States
      2023   Phase 3   EUCTR2020-005992-10-BE   Belgium;Canada;Czechia;France;Germany;Italy;Poland;Spain;United Kingdom;United States
      2023   Phase 3   EUCTR2020-005991-36-PL   Belgium;Canada;Czechia;France;Germany;Italy;Poland;Spain;United Kingdom;United States
      2023   Phase 3   EUCTR2020-005991-36-BE   Belgium;Canada;Czechia;France;Germany;Italy;Poland;Spain;United Kingdom;United States
      2022   Phase 3   NCT04786574   Belgium;Germany;Italy;Poland;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2020-005991-36-DE   Belgium;Canada;Czechia;France;Germany;Italy;Poland;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2016-000187-42-IT   Belgium;Germany;Hungary;Italy;Poland;Spain;United Kingdom
      2016   Phase 3   EUCTR2016-000187-42-GB   Belgium;Germany;Italy;United Kingdom
      2016   Phase 3   EUCTR2016-000187-42-DE   Belgium;Germany;Italy;United Kingdom
      2016   Phase 3   EUCTR2016-000187-42-BE   Belgium;Germany;Italy;United Kingdom
      2015   Phase 3   EUCTR2014-000226-38-PL   Argentina;Australia;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States
      2015   Phase 3   EUCTR2014-000226-38-GB   Argentina;Australia;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States
      2015   Phase 3   EUCTR2014-000226-38-FR   Argentina;Australia;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States
      2015   Phase 3   EUCTR2014-000226-38-ES   Argentina;Australia;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States
      2015   Phase 3   EUCTR2014-000226-38-CZ   Argentina;Australia;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States
      2014   Phase 3   NCT02160145   Argentina;Australia;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Norway;Poland;Puerto Rico;Romania;Russian Federation;South Africa;Spain;Sweden;United Kingdom;United States
      2014   Phase 3   EUCTR2014-000226-38-SE   Argentina;Australia;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2014-000226-38-NL   Argentina;Australia;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2014-000226-38-IT   Argentina;Australia;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2014-000226-38-HU   Argentina;Australia;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2014-000226-38-DK   Argentina;Australia;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2014-000226-38-BE   Argentina;Australia;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States
      2007   Phase 3   EUCTR2006-002768-24-GB   Belgium;Denmark;France;Germany;Italy;United Kingdom
      2007   -   EUCTR2006-002768-24-DK   Denmark;France;Germany;Italy;United Kingdom
      2007   -   EUCTR2006-002768-24-DE   Denmark;France;Germany;Italy;United Kingdom
      -   Phase 3   EUCTR2020-005992-10-DE   Belgium;Canada;Czechia;France;Germany;Italy;Poland;Spain;United Kingdom;United States
   Otsuka Pharmaceutical Development & Commercialization. Inc.
      2007   Phase 3   EUCTR2006-002768-24-BE   Belgium;Denmark;France;Germany;Italy;United Kingdom
   Otsuka Pharmaceutical Development Commercialization, Inc.
      2010   -   EUCTR2010-019025-33-NL   Netherlands
Pasireotide LAR
   Mayo Clinic
      2012   Phase 2   NCT01670110   United States
PET/CT scan
   University of Colorado, Denver
      2020   -   NCT04407481   United States
PF-05208763
   PFIZER INC.
      2011   -   EUCTR2010-023017-65-IT   Australia;Canada;Czech Republic;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Lithuania;Poland;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
   PFIZER, S.L.U.
      2011   -   EUCTR2010-023017-65-ES   Czech Republic;Hungary;Italy;Lithuania;Poland;Slovakia;Spain;Sweden;United Kingdom
   Pfizer Inc.
      2011   -   EUCTR2010-023017-65-CZ   Australia;Bulgaria;Canada;Czech Republic;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Lithuania;Moldova, Republic of;Poland;Romania;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
   Pfizer Inc., 235 East 42nd Street, New York, NY 10017
      2012   Phase 2   EUCTR2010-023017-65-BG   Australia;Bulgaria;Canada;Czech Republic;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Lithuania;Moldova, Republic of;Poland;Romania;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2011   Phase 2   EUCTR2010-023017-65-SK   Australia;Bulgaria;Canada;Czech Republic;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Lithuania;Moldova, Republic of;Poland;Romania;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2011   -   EUCTR2010-023017-65-SE   Australia;Bulgaria;Canada;Czech Republic;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Lithuania;Moldova, Republic of;Poland;Romania;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2011   -   EUCTR2010-023017-65-PL   Czech Republic;Hungary;Italy;Lithuania;Poland;Slovakia;Spain;Sweden;United Kingdom
      2011   -   EUCTR2010-023017-65-LT   Czech Republic;Hungary;Italy;Lithuania;Poland;Slovakia;Spain;Sweden;United Kingdom
      2011   -   EUCTR2010-023017-65-HU   Australia;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Lithuania;Moldova, Republic of;Poland;Romania;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2011   Phase 2   EUCTR2010-023017-65-GB   Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Lithuania;Poland;Romania;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
Pioglitazone
   Indiana University
      2016   Phase 2   NCT02697617   United States
Plcacebo
   Jemincare
      2025   Phase 2   NCT06800651   -
Potassium
   Shanghai Changzheng Hospital
      2011   -   ChiCTR-TRC-11001282   China
Pravastatin
   University of Colorado, Denver
      2017   Phase 4   NCT03273413   United States
      2006   Phase 3   NCT00456365   United States
   University of Southern California
      2019   Phase 2   NCT04284657   United States
Protein
   Esther Meijer
      2020   -   NCT04310319   Netherlands
PYC-003
   PYC Therapeutics
      2025   Phase 1   NCT06714006   Australia
RAD001
   Novartis Pharma GmbH
      2007   -   EUCTR2006-001485-16-FR   Austria;France;Germany
      2006   -   EUCTR2006-001485-16-DE   Austria;France;Germany
      2006   -   EUCTR2006-001485-16-AT   Austria;France;Germany
Ramipril
   AZIENDA OSPEDALIERA OSPEDALE POLICLINICO CONSORZIALE
      2007   -   EUCTR2007-006557-25-IT   Italy
Rapamune
   The Cleveland Clinic
      2006   Phase 1/Phase 2   NCT00286156   United States
Rapamune 1MG tablets
   Medizinische Universität Wien, Klinische Abteilung für Nephrologie und Dialyse, Universitätsklinik für Innere Medizin 3
      2014   Phase 3   EUCTR2012-000550-60-AT   Austria
Rapamune*100CPR RIV 1MG
   AZIENDA OSPEDALIERA OSPEDALE POLICLINICO CONSORZIALE
      2007   -   EUCTR2007-006557-25-IT   Italy
   IST. DI RICERCHE FARMACOLOG. M. NEGRI
      2007   Phase 2   EUCTR2007-005047-21-IT   Italy
Rapamune*30CPR RIV 1MG
   IST. DI RICERCHE FARMACOLOG. M. NEGRI
      2007   Phase 2   EUCTR2006-003427-37-IT   Italy
Rapamune*30CPR RIV 2MG
   IST. DI RICERCHE FARMACOLOG. M. NEGRI
      2007   Phase 2   EUCTR2007-005047-21-IT   Italy
      2007   Phase 2   EUCTR2006-003427-37-IT   Italy
Rapamycin
   Yale University
      2009   Phase 2/Phase 3   NCT00920309   United States
Renal sympathetic denervation
   Mei changlin
      2013   Phase 2   NCT01932450   China
RGLS4326
   Regulus Therapeutics Inc.
      2020   Phase 1   NCT04536688   United States
RGLS8429
   Regulus Therapeutics Inc.
      2022   Phase 1   NCT05521191   United States
Rotigotine
   University Hospital, Rouen
      2025   Phase 2   NCT06291116   -
RTA 402
   REATA PHARMACEUTICALS, INC.
      2019   Phase 3   EUCTR2018-004651-20-IT   Australia;Belgium;Czech Republic;Czechia;France;Germany;Italy;Spain;United Kingdom;United States
   Reata Pharmaceuticals, Inc.
      2023   Phase 3   EUCTR2018-004651-20-PL   Australia;Belgium;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Italy;Japan;Poland;Spain;United Kingdom;United States
      2023   Phase 3   EUCTR2018-004651-20-HU   Australia;Belgium;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Italy;Japan;Poland;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2018-004651-20-GB   Australia;Belgium;Czech Republic;France;Germany;Italy;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2018-004651-20-DE   Australia;Belgium;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Italy;Japan;Poland;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-004651-20-FR   Australia;Belgium;Czech Republic;Denmark;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-004651-20-ES   Australia;Belgium;Czech Republic;France;Germany;Italy;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-004651-20-CZ   Australia;Belgium;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Italy;Japan;Poland;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-004651-20-BE   Australia;Belgium;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Italy;Japan;Poland;Spain;United Kingdom;United States
Saline
   Assistance Publique - Hôpitaux de Paris
      2014   Phase 3   NCT02127437   France
Saline solution
   Mario Negri Institute for Pharmacological Research
      2011   Phase 3   NCT01377246   Italy
      2006   Phase 3   NCT00309283   Italy
Samsca
   Department of Medical Research
      2015   Phase 2   EUCTR2015-001903-30-DK   Denmark
   Otsuka Pharmaceutical Development & Commercialization, Inc
      2011   -   EUCTR2010-018401-10-NL   Afghanistan;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Romania;Russian Federation;United Kingdom;United States
   University Clinic in Nephrology and Hypertension, Department of Medical Research
      2014   -   EUCTR2014-001973-15-DK   Denmark
Samsca 15 MG tablets
   Otsuka Pharmaceutical Development & Commercialization, Inc
      2010   Phase 3   EUCTR2010-018401-10-GB   Argentina;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Romania;Russian Federation;United Kingdom;United States
      2010   Phase 3   EUCTR2010-018401-10-FR   Belgium;France;Germany;Italy;Netherlands;United Kingdom
      2010   -   EUCTR2010-018401-10-DE   Argentina;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Romania;Russian Federation;United Kingdom;United States
      2010   Phase 3   EUCTR2010-018401-10-BE   Argentina;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Romania;Russian Federation;United Kingdom;United States
   Otsuka Pharmaceutical Development Commercialization, Inc.
      2010   -   EUCTR2010-019025-33-NL   Netherlands
Samsca 30 MG tablets
   Otsuka Pharmaceutical Development & Commercialization, Inc
      2010   Phase 3   EUCTR2010-018401-10-GB   Argentina;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Romania;Russian Federation;United Kingdom;United States
      2010   Phase 3   EUCTR2010-018401-10-FR   Belgium;France;Germany;Italy;Netherlands;United Kingdom
      2010   -   EUCTR2010-018401-10-DE   Argentina;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Romania;Russian Federation;United Kingdom;United States
      2010   Phase 3   EUCTR2010-018401-10-BE   Argentina;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Romania;Russian Federation;United Kingdom;United States
   Otsuka Pharmaceutical Development Commercialization, Inc.
      2010   -   EUCTR2010-019025-33-NL   Netherlands
Samsca 7.5 MG oral tablet
   Otsuka Pharmaceutical Development & Commercialization, Inc.
      2023   Phase 3   EUCTR2020-005992-10-PL   Belgium;Canada;Czechia;France;Germany;Italy;Poland;Spain;United Kingdom;United States
      2023   Phase 3   EUCTR2020-005992-10-BE   Belgium;Canada;Czechia;France;Germany;Italy;Poland;Spain;United Kingdom;United States
      -   Phase 3   EUCTR2020-005992-10-DE   Belgium;Canada;Czechia;France;Germany;Italy;Poland;Spain;United Kingdom;United States
Sandostatin LAR
   Radboud University Nijmegen Medical Centre
      2011   Phase 4   EUCTR2009-017849-57-NL   Netherlands
Sandostatina - LAR 20 MG/2.5 ML polvere E solvente PER sospensione iniettabile flacone polvere + siringa preriempita 2.5 ML + 2 aghi
   IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
      2018   Phase 2   EUCTR2017-004701-40-IT   Italy
Sandostatina LAR
   IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
      2018   Phase 2   EUCTR2017-004701-40-IT   Italy
   IST. DI RICERCHE FARMACOLOG. M. NEGRI
      2011   Phase 3   EUCTR2011-000138-12-IT   Italy
      2009   Phase 3   EUCTR2009-012376-27-IT   Italy
Sandostatina LAR IM FL 20MG +2F
   IST. DI RICERCHE FARMACOLOG. M. NEGRI
      2006   Phase 3   EUCTR2005-005552-41-IT   Italy
SAR402671, GZ402671 or GZ/SAR402671
   Genzyme Corporation
      2019   Phase 2   EUCTR2017-004084-12-RO   Australia;Austria;Belgium;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Spain;Switzerland;Taiwan;United Kingdom;United States
      2019   Phase 2   EUCTR2017-004084-12-NL   Argentina;Australia;Austria;Belgium;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Spain;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 2   EUCTR2017-004084-12-GB   Australia;Austria;Belgium;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Spain;Switzerland;Taiwan;United Kingdom;United States
      2019   Phase 2   EUCTR2017-004084-12-AT   Australia;Austria;Belgium;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Spain;Switzerland;Taiwan;United Kingdom;United States
      2018   Phase 2   EUCTR2017-004084-12-PT   Australia;Austria;Belgium;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Spain;Switzerland;Taiwan;United Kingdom;United States
      2018   Phase 2   EUCTR2017-004084-12-ES   Australia;Austria;Belgium;Canada;China;Czech Republic;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Spain;Switzerland;Taiwan;United Kingdom;United States
      2018   Phase 2   EUCTR2017-004084-12-DK   Australia;Austria;Belgium;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Spain;Switzerland;Taiwan;United Kingdom;United States
      2018   Phase 2   EUCTR2017-004084-12-DE   Australia;Austria;Belgium;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Spain;Switzerland;Taiwan;United Kingdom;United States
      2018   Phase 2   EUCTR2017-004084-12-CZ   Australia;Austria;Belgium;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Spain;Taiwan;United Kingdom;United States
      2018   Phase 2   EUCTR2017-004084-12-BE   Australia;Austria;Belgium;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Spain;Taiwan;United Kingdom;United States
   Sanofi-Aventis Recherche & Développement
      2021   Phase 3   EUCTR2020-004400-34-PT   Argentina;Australia;Belgium;Canada;China;Czechia;Denmark;France;Germany;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Romania;Spain;Taiwan;Turkey;United Kingdom
      2021   Phase 3   EUCTR2020-004400-34-NL   Argentina;Australia;Belgium;Canada;China;Czech Republic;Denmark;France;Germany;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Romania;Spain;Taiwan;Turkey;United Kingdom
      2021   Phase 3   EUCTR2020-004400-34-FR   Argentina;Australia;Belgium;Canada;China;Czechia;Denmark;France;Germany;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Romania;Spain;Taiwan;Turkey;United Kingdom
      2021   Phase 3   EUCTR2020-004400-34-DE   Argentina;Australia;Belgium;Canada;China;Czechia;Denmark;France;Germany;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Romania;Spain;Taiwan;Turkey;United Kingdom
      2021   Phase 3   EUCTR2020-004400-34-BE   Argentina;Australia;Belgium;Canada;China;Czechia;Denmark;France;Germany;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Romania;Spain;Taiwan;Turkey;United Kingdom
Sirolimus
   AZIENDA OSPEDALIERA OSPEDALE POLICLINICO CONSORZIALE
      2007   -   EUCTR2007-006557-25-IT   Italy
   IST. DI RICERCHE FARMACOLOG. M. NEGRI
      2007   Phase 2   EUCTR2007-005047-21-IT   Italy
      2007   Phase 2   EUCTR2006-003427-37-IT   Italy
   Mario Negri Institute for Pharmacological Research
      2010   Phase 2/Phase 3   NCT01223755   Italy
      2007   Phase 2   NCT00491517   Italy
   Medical University of Vienna
      2014   Phase 3   NCT02055079   Austria
      2009   -   NCT01632605   Austria
   Medizinische Universität Wien, Klinische Abteilung für Nephrologie und Dialyse, Universitätsklinik für Innere Medizin 3
      2014   Phase 3   EUCTR2012-000550-60-AT   Austria
   Seoul National University Hospital
      2011   Phase 2/Phase 3   NCT01680250   Korea, Republic of
   University of Zurich
      2006   Phase 3   NCT00346918   Switzerland
SKI-606
   PFIZER INC.
      2011   -   EUCTR2010-023017-65-IT   Australia;Canada;Czech Republic;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Lithuania;Poland;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
   PFIZER, S.L.U.
      2011   -   EUCTR2010-023017-65-ES   Czech Republic;Hungary;Italy;Lithuania;Poland;Slovakia;Spain;Sweden;United Kingdom
   Pfizer Inc.
      2011   -   EUCTR2010-023017-65-CZ   Australia;Bulgaria;Canada;Czech Republic;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Lithuania;Moldova, Republic of;Poland;Romania;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
   Pfizer Inc., 235 East 42nd Street, New York, NY 10017
      2012   Phase 2   EUCTR2010-023017-65-BG   Australia;Bulgaria;Canada;Czech Republic;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Lithuania;Moldova, Republic of;Poland;Romania;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2011   Phase 2   EUCTR2010-023017-65-SK   Australia;Bulgaria;Canada;Czech Republic;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Lithuania;Moldova, Republic of;Poland;Romania;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2011   -   EUCTR2010-023017-65-SE   Australia;Bulgaria;Canada;Czech Republic;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Lithuania;Moldova, Republic of;Poland;Romania;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2011   -   EUCTR2010-023017-65-PL   Czech Republic;Hungary;Italy;Lithuania;Poland;Slovakia;Spain;Sweden;United Kingdom
      2011   -   EUCTR2010-023017-65-LT   Czech Republic;Hungary;Italy;Lithuania;Poland;Slovakia;Spain;Sweden;United Kingdom
      2011   -   EUCTR2010-023017-65-HU   Australia;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Lithuania;Moldova, Republic of;Poland;Romania;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2011   Phase 2   EUCTR2010-023017-65-GB   Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Lithuania;Poland;Romania;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
Sodium bicarbonate 600 MG oral tablet
   Taipei Medical University Shuang Ho Hospital
      2023   Phase 2   NCT05870007   Taiwan
Sodium chloride
   Erasmus Medical Center
      2022   Phase 4   NCT05228574   Netherlands
   Erasmus University Medical Centre Rotterdam
      2021   Phase 4   EUCTR2020-000433-40-NL   Netherlands
Sodium citrate
   University of Southern California
      2019   Phase 2   NCT04284657   United States
Sodium pyruvate
   Aarhus University
      2022   Phase 2   EUCTR2021-002551-11-DK   Denmark
Sodiumchloride
   Esther Meijer
      2020   -   NCT04310319   Netherlands
Somatuline autogel
   DIPAK Consortium
      2012   Phase 3   EUCTR2011-005017-37-NL   Netherlands
Somatuline autosolution
   Radboud University Nijmegen Medical Centre
      2011   Phase 4   EUCTR2009-017849-57-NL   Netherlands
Spironolactone
   University of Colorado, Denver
      2013   Phase 3   NCT01853553   United States
Standard
   Nephrology Center, Toranomon Hospital
      2014   -   JPRN-UMIN000012865   Japan
   University Hospital, Rouen
      2025   Phase 2   NCT06291116   -
   University of Zurich
      2006   Phase 3   NCT00346918   Switzerland
   Yale University
      2009   Phase 2/Phase 3   NCT00920309   United States
Standard blood pressure control
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      2006   Phase 3   NCT00283686   United States
Sugar pill
   University of Colorado, Denver
      2013   Phase 3   NCT01853553   United States
Tamibarotene
   Hayashi Ayuto
      2023   Phase 2   JPRN-jRCT2011230055   -
   Rege Nephro Co., Ltd.
      2023   Phase 2   NCT06289998   Japan
Telmisartan
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      2006   Phase 3   NCT01885559   United States
      2006   Phase 3   NCT00283686   United States
Tesevatinib
   Kadmon Corporation, LLC
      2017   Phase 1   NCT03096080   United States
      2015   Phase 2   NCT02616055   United States
   Kadmon, a Sanofi Company
      2017   Phase 2   NCT03203642   United States
      2012   Phase 1/Phase 2   NCT01559363   United States
Tetracosactin
   Istanbul University
      2006   -   NCT00598377   Turkey
Tirzepatide
   University of Colorado, Denver
      2025   Phase 2   NCT06582875   United States
Tolvaptan
   Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari
      2019   Phase 3   NCT03764605   Italy
   Department of Medical Research
      2015   Phase 2   EUCTR2015-001903-30-DK   Denmark
   Department of Nephrology, Tokyo Women's Medical University
      2014   -   JPRN-UMIN000015245   Japan
   Hangzhou hospital of Traditional Chinese Medicine
      2022   Phase 1   ChiCTR2200058370   China
   Horie Shigeo
      2019   -   JPRN-jRCTs031180259   -
   IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
      2018   Phase 2   EUCTR2017-004701-40-IT   Italy
   Korea Otsuka Pharmaceutical Co., Ltd.
      2019   Phase 4   NCT03949894   Korea, Republic of
      2016   -   NCT03406286   Korea, Republic of
   Kyorin University
      2016   -   NCT02729662   Japan
   Kyorin University School of Medicine
      2014   Phase 4   JPRN-UMIN000015715   Japan
   Lisbet Brandi
      2018   Phase 4   NCT03596957   Denmark
   Mario Negri Institute for Pharmacological Research
      2018   Phase 2   NCT03541447   Italy
   OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALISATION INC
      2007   -   EUCTR2006-002768-24-IT   Denmark;France;Germany;Italy;United Kingdom
   Otsuka Maryland Research Institute, Inc.
      2007   Phase 3   EUCTR2006-002768-24-FR   Belgium;Denmark;France;Germany;Italy;United Kingdom
   Otsuka Pharmaceutical Co., Ltd.
      2014   -   NCT02847624   Japan
      2010   Phase 3   NCT01280721   Japan
      2010   Phase 3   JPRN-jRCT2080221325   -
   Otsuka Pharmaceutical Development & Commercialization, Inc
      2011   -   EUCTR2010-018401-10-NL   Afghanistan;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Romania;Russian Federation;United Kingdom;United States
   Otsuka Pharmaceutical Development & Commercialization, Inc.
      2022   Phase 3   NCT04786574   Belgium;Germany;Italy;Poland;Spain;United Kingdom;United States
      2016   Phase 3   NCT02964273   Belgium;Germany;Italy;United Kingdom
      2016   Phase 3   EUCTR2014-001501-41-BE   Argentina;Belgium;France;Germany;Japan;United States
      2015   Phase 3   EUCTR2014-001501-41-FR   Argentina;Belgium;France;Germany;Japan;United States
      2014   Phase 3   NCT02251275   Argentina;Australia;Belgium;Canada;Czech Republic;Czechia;Denmark;Germany;Hungary;Israel;Italy;Netherlands;Norway;Poland;Romania;Russian Federation;South Africa;Spain;Sweden;United Kingdom;United States
      2014   Phase 3   NCT02160145   Argentina;Australia;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Norway;Poland;Puerto Rico;Romania;Russian Federation;South Africa;Spain;Sweden;United Kingdom;United States
      2010   Phase 2   NCT01336972   Netherlands
      2010   Phase 3   NCT01214421   Argentina;Australia;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Romania;Russian Federation;United Kingdom;United States
      2007   Phase 3   NCT00428948   Argentina;Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;United Kingdom;United States
      2007   Phase 3   EUCTR2006-002768-24-GB   Belgium;Denmark;France;Germany;Italy;United Kingdom
      2007   -   EUCTR2006-002768-24-DK   Denmark;France;Germany;Italy;United Kingdom
      2007   -   EUCTR2006-002768-24-DE   Denmark;France;Germany;Italy;United Kingdom
      2005   Phase 2   NCT00413777   United States
   Otsuka Pharmaceutical Development & Commercialization. Inc.
      2007   Phase 3   EUCTR2006-002768-24-BE   Belgium;Denmark;France;Germany;Italy;United Kingdom
   Regional Hospital Holstebro
      2015   Phase 3   NCT03803124   Denmark
      2015   Phase 2   NCT02527863   Denmark
   University Clinic in Nephrology and Hypertension, Department of Medical Research
      2014   -   EUCTR2014-001973-15-DK   Denmark
Tolvaptan 15
   U.O. NEFROLOGIA, DIALISI E TRAPIANTO AZIENDA OSPEDALIERO UNIVERSITARIA POLICLINICO DI BARI
      2018   Phase 3   EUCTR2018-000477-77-IT   Italy
Tolvaptan 15 MG tablet
   Otsuka Pharmaceutical Development & Commercialization, Inc.
      2023   Phase 3   EUCTR2020-005992-10-PL   Belgium;Canada;Czechia;France;Germany;Italy;Poland;Spain;United Kingdom;United States
      2023   Phase 3   EUCTR2020-005992-10-BE   Belgium;Canada;Czechia;France;Germany;Italy;Poland;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2016-000187-42-IT   Belgium;Germany;Hungary;Italy;Poland;Spain;United Kingdom
      2016   Phase 3   EUCTR2016-000187-42-GB   Belgium;Germany;Italy;United Kingdom
      2016   Phase 3   EUCTR2016-000187-42-DE   Belgium;Germany;Italy;United Kingdom
      2016   Phase 3   EUCTR2016-000187-42-BE   Belgium;Germany;Italy;United Kingdom
      -   Phase 3   EUCTR2020-005992-10-DE   Belgium;Canada;Czechia;France;Germany;Italy;Poland;Spain;United Kingdom;United States
Tolvaptan 15 MG tablets
   Otsuka Pharmaceutical Development & Commercialization, Inc
      2010   Phase 3   EUCTR2010-018401-10-GB   Argentina;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Romania;Russian Federation;United Kingdom;United States
      2010   Phase 3   EUCTR2010-018401-10-FR   Belgium;France;Germany;Italy;Netherlands;United Kingdom
      2010   -   EUCTR2010-018401-10-DE   Argentina;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Romania;Russian Federation;United Kingdom;United States
      2010   Phase 3   EUCTR2010-018401-10-BE   Argentina;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Romania;Russian Federation;United Kingdom;United States
   Otsuka Pharmaceutical Development Commercialization, Inc.
      2010   -   EUCTR2010-019025-33-NL   Netherlands
Tolvaptan 15MG
   Otsuka Pharmaceutical Development & Commercialization, Inc.
      2015   Phase 3   EUCTR2014-000226-38-PL   Argentina;Australia;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States
      2015   Phase 3   EUCTR2014-000226-38-GB   Argentina;Australia;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States
      2015   Phase 3   EUCTR2014-000226-38-FR   Argentina;Australia;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States
      2015   Phase 3   EUCTR2014-000226-38-ES   Argentina;Australia;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States
      2015   Phase 3   EUCTR2014-000226-38-CZ   Argentina;Australia;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2014-000226-38-SE   Argentina;Australia;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2014-000226-38-NL   Argentina;Australia;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2014-000226-38-IT   Argentina;Australia;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2014-000226-38-HU   Argentina;Australia;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2014-000226-38-DK   Argentina;Australia;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2014-000226-38-BE   Argentina;Australia;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States
Tolvaptan 30
   U.O. NEFROLOGIA, DIALISI E TRAPIANTO AZIENDA OSPEDALIERO UNIVERSITARIA POLICLINICO DI BARI
      2018   Phase 3   EUCTR2018-000477-77-IT   Italy
Tolvaptan 30 MG tablet
   Otsuka Pharmaceutical Development & Commercialization, Inc.
      2023   Phase 3   EUCTR2020-005992-10-PL   Belgium;Canada;Czechia;France;Germany;Italy;Poland;Spain;United Kingdom;United States
      2023   Phase 3   EUCTR2020-005992-10-BE   Belgium;Canada;Czechia;France;Germany;Italy;Poland;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2016-000187-42-IT   Belgium;Germany;Hungary;Italy;Poland;Spain;United Kingdom
      2016   Phase 3   EUCTR2016-000187-42-GB   Belgium;Germany;Italy;United Kingdom
      2016   Phase 3   EUCTR2016-000187-42-DE   Belgium;Germany;Italy;United Kingdom
      2016   Phase 3   EUCTR2016-000187-42-BE   Belgium;Germany;Italy;United Kingdom
      -   Phase 3   EUCTR2020-005992-10-DE   Belgium;Canada;Czechia;France;Germany;Italy;Poland;Spain;United Kingdom;United States
Tolvaptan 30 MG tablets
   Otsuka Pharmaceutical Development & Commercialization, Inc
      2010   Phase 3   EUCTR2010-018401-10-GB   Argentina;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Romania;Russian Federation;United Kingdom;United States
      2010   Phase 3   EUCTR2010-018401-10-FR   Belgium;France;Germany;Italy;Netherlands;United Kingdom
      2010   -   EUCTR2010-018401-10-DE   Argentina;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Romania;Russian Federation;United Kingdom;United States
      2010   Phase 3   EUCTR2010-018401-10-BE   Argentina;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Romania;Russian Federation;United Kingdom;United States
   Otsuka Pharmaceutical Development Commercialization, Inc.
      2010   -   EUCTR2010-019025-33-NL   Netherlands
Tolvaptan 30MG
   Otsuka Pharmaceutical Development & Commercialization, Inc.
      2015   Phase 3   EUCTR2014-000226-38-PL   Argentina;Australia;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States
      2015   Phase 3   EUCTR2014-000226-38-GB   Argentina;Australia;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States
      2015   Phase 3   EUCTR2014-000226-38-FR   Argentina;Australia;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States
      2015   Phase 3   EUCTR2014-000226-38-ES   Argentina;Australia;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States
      2015   Phase 3   EUCTR2014-000226-38-CZ   Argentina;Australia;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2014-000226-38-SE   Argentina;Australia;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2014-000226-38-NL   Argentina;Australia;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2014-000226-38-IT   Argentina;Australia;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2014-000226-38-HU   Argentina;Australia;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2014-000226-38-DK   Argentina;Australia;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2014-000226-38-BE   Argentina;Australia;Belgium;Brazil;Canada;Chile;Colombia;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States
Tolvaptan 45/15
   U.O. NEFROLOGIA, DIALISI E TRAPIANTO AZIENDA OSPEDALIERO UNIVERSITARIA POLICLINICO DI BARI
      2018   Phase 3   EUCTR2018-000477-77-IT   Italy
Tolvaptan 50MG granules
   Otsuka Pharmaceutical Development & Commercialization, Inc.
      2023   Phase 3   EUCTR2020-005992-10-PL   Belgium;Canada;Czechia;France;Germany;Italy;Poland;Spain;United Kingdom;United States
      2023   Phase 3   EUCTR2020-005992-10-BE   Belgium;Canada;Czechia;France;Germany;Italy;Poland;Spain;United Kingdom;United States
      2023   Phase 3   EUCTR2020-005991-36-PL   Belgium;Canada;Czechia;France;Germany;Italy;Poland;Spain;United Kingdom;United States
      2023   Phase 3   EUCTR2020-005991-36-BE   Belgium;Canada;Czechia;France;Germany;Italy;Poland;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2020-005991-36-DE   Belgium;Canada;Czechia;France;Germany;Italy;Poland;Spain;United Kingdom;United States
      -   Phase 3   EUCTR2020-005992-10-DE   Belgium;Canada;Czechia;France;Germany;Italy;Poland;Spain;United Kingdom;United States
Tolvaptan 60/30
   U.O. NEFROLOGIA, DIALISI E TRAPIANTO AZIENDA OSPEDALIERO UNIVERSITARIA POLICLINICO DI BARI
      2018   Phase 3   EUCTR2018-000477-77-IT   Italy
Tolvaptan 7.5 MG tablet
   Otsuka Pharmaceutical Development & Commercialization, Inc.
      2023   Phase 3   EUCTR2020-005992-10-PL   Belgium;Canada;Czechia;France;Germany;Italy;Poland;Spain;United Kingdom;United States
      2023   Phase 3   EUCTR2020-005992-10-BE   Belgium;Canada;Czechia;France;Germany;Italy;Poland;Spain;United Kingdom;United States
      2016   Phase 3   EUCTR2016-000187-42-IT   Belgium;Germany;Hungary;Italy;Poland;Spain;United Kingdom
      2016   Phase 3   EUCTR2016-000187-42-GB   Belgium;Germany;Italy;United Kingdom
      2016   Phase 3   EUCTR2016-000187-42-DE   Belgium;Germany;Italy;United Kingdom
      2016   Phase 3   EUCTR2016-000187-42-BE   Belgium;Germany;Italy;United Kingdom
      -   Phase 3   EUCTR2020-005992-10-DE   Belgium;Canada;Czechia;France;Germany;Italy;Poland;Spain;United Kingdom;United States
Tolvaptan IR
   Otsuka Pharmaceutical Development & Commercialization, Inc.
      2011   Phase 2   NCT01451827   United States
      2010   Phase 2   NCT01210560   United States
Tolvaptan MR
   Otsuka Pharmaceutical Development & Commercialization, Inc.
      2011   Phase 2   NCT01451827   United States
      2010   Phase 2   NCT01210560   United States
Tolvaptan suspension
   Otsuka Pharmaceutical Development & Commercialization, Inc.
      2022   Phase 3   NCT04782258   Belgium;France;Germany;Italy;Poland;Spain;United Kingdom;United States
Tolvaptan tablets
   Otsuka Pharmaceutical Development & Commercialization, Inc.
      2022   Phase 3   NCT04782258   Belgium;France;Germany;Italy;Poland;Spain;United Kingdom;United States
Tripterygium wilfordii
   Zhi-Hong Liu, M.D.
      2008   -   NCT00801268   China
Triptolide-containing formulation
   Shanghai Changzheng Hospital
      2014   Phase 3   NCT02115659   China
Udca
   Nephrology Center, Toranomon Hospital
      2014   -   JPRN-UMIN000012865   Japan
Unknown
   Radboud University Nijmegen Medical Centre
      2011   Phase 4   EUCTR2009-017849-57-NL   Netherlands
Ursochol 300
   Radboud University Nijmegen Medical Center
      2013   Phase 4   EUCTR2013-003207-19-NL   Netherlands;Spain
Ursodeoxycholic acid
   Radboud University
      2013   Phase 2   NCT02021110   Netherlands;Spain
Venglustat
   Beijing Hospital
      2021   Phase 1   ChiCTR2200066559   China
   GENZYME CORPORATION
      2018   Phase 2   EUCTR2017-004084-12-IT   Australia;Austria;Belgium;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Spain;Taiwan;United Kingdom;United States
   Genzyme Corporation
      2019   Phase 2   EUCTR2017-004084-12-RO   Australia;Austria;Belgium;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Spain;Switzerland;Taiwan;United Kingdom;United States
      2019   Phase 2   EUCTR2017-004084-12-NL   Argentina;Australia;Austria;Belgium;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Spain;Taiwan;Turkey;United Kingdom;United States
      2019   Phase 2   EUCTR2017-004084-12-GB   Australia;Austria;Belgium;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Spain;Switzerland;Taiwan;United Kingdom;United States
      2019   Phase 2   EUCTR2017-004084-12-AT   Australia;Austria;Belgium;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Spain;Switzerland;Taiwan;United Kingdom;United States
      2018   Phase 2   EUCTR2017-004084-12-PT   Australia;Austria;Belgium;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Spain;Switzerland;Taiwan;United Kingdom;United States
      2018   Phase 2   EUCTR2017-004084-12-ES   Australia;Austria;Belgium;Canada;China;Czech Republic;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Spain;Switzerland;Taiwan;United Kingdom;United States
      2018   Phase 2   EUCTR2017-004084-12-DK   Australia;Austria;Belgium;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Spain;Switzerland;Taiwan;United Kingdom;United States
      2018   Phase 2   EUCTR2017-004084-12-DE   Australia;Austria;Belgium;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Spain;Switzerland;Taiwan;United Kingdom;United States
      2018   Phase 2   EUCTR2017-004084-12-CZ   Australia;Austria;Belgium;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Spain;Taiwan;United Kingdom;United States
      2018   Phase 2   EUCTR2017-004084-12-BE   Australia;Austria;Belgium;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;Portugal;Romania;Spain;Taiwan;United Kingdom;United States
   Genzyme, a Sanofi Company
      2018   Phase 2/Phase 3   NCT03523728   Argentina;Australia;Austria;Belgium;Canada;China;Czechia;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Romania;Spain;Taiwan;Turkey;United Kingdom;United States
   Sanofi K.K.
      2019   Phase 2-3   JPRN-jRCT2080224131   Asia except Japan;Europe;Japan;North America;Oceania;South America
   Tanaka Tomoyuki
      2021   Phase 3   JPRN-jRCT2031200348   Australia;Germany;Japan;Netherlands;Republic of Korea;Spain;United States
Venglustat GZ/SAR402671
   Genzyme, a Sanofi Company
      2018   Phase 1   NCT03687554   United States
Venglustat GZ402671
   Sanofi
      2021   Phase 3   NCT04705051   Australia;Belgium;France;Germany;Japan;Korea, Republic of;Netherlands;Romania;Spain;United States
Venglustat malate
   Sanofi-Aventis Recherche & Développement
      2021   Phase 3   EUCTR2020-004400-34-PT   Argentina;Australia;Belgium;Canada;China;Czechia;Denmark;France;Germany;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Romania;Spain;Taiwan;Turkey;United Kingdom
      2021   Phase 3   EUCTR2020-004400-34-NL   Argentina;Australia;Belgium;Canada;China;Czech Republic;Denmark;France;Germany;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Romania;Spain;Taiwan;Turkey;United Kingdom
      2021   Phase 3   EUCTR2020-004400-34-FR   Argentina;Australia;Belgium;Canada;China;Czechia;Denmark;France;Germany;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Romania;Spain;Taiwan;Turkey;United Kingdom
      2021   Phase 3   EUCTR2020-004400-34-DE   Argentina;Australia;Belgium;Canada;China;Czechia;Denmark;France;Germany;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Romania;Spain;Taiwan;Turkey;United Kingdom
      2021   Phase 3   EUCTR2020-004400-34-BE   Argentina;Australia;Belgium;Canada;China;Czechia;Denmark;France;Germany;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Romania;Spain;Taiwan;Turkey;United Kingdom
Venglustat malato
   SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
      2021   Phase 3   EUCTR2020-004400-34-IT   Argentina;Australia;Belgium;Canada;China;Czechia;Denmark;France;Germany;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Romania;Spain;Taiwan;Turkey;United Kingdom
VX-407
   Vertex Pharmaceuticals Incorporated
      2024   Phase 1   NCT06345755   Canada;United States
Water
   New York University School of Medicine
      2008   -   NCT00784030   United States
   Rigshospitalet, Denmark
      2015   -   NCT02776241   Denmark
Water prescription
   University of Kansas
      2008   -   NCT00759369   United States
Zestril
   Addenbrooke's Hospital Trust
      2005   Phase 4   EUCTR2005-003182-16-GB   United Kingdom
Zuglimet - 500 MG compresse rivestite CON film 30 compresse IN blister PVC/AL
   U.O. NEFROLOGIA, DIALISI E TRAPIANTO AZIENDA OSPEDALIERO UNIVERSITARIA POLICLINICO DI BARI
      2018   Phase 3   EUCTR2018-000477-77-IT   Italy